426 related articles for article (PubMed ID: 10959704)
21. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents.
Longstaff C
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):537-42. PubMed ID: 7531000
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen-plasmin system IX. Specific binding of tranexamic acid to plasmin.
Iwamoto M
Thromb Diath Haemorrh; 1975 Jun; 33(3):573-85. PubMed ID: 125463
[TBL] [Abstract][Full Text] [Related]
23. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
Holvoet P; de Boer A; Verstreken M; Collen D
Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
[TBL] [Abstract][Full Text] [Related]
24. Detection of the plasmin system in human mammary pathology using immunofluorescence.
Clavel C; Chavanel G; Birembaut P
Cancer Res; 1986 Nov; 46(11):5743-7. PubMed ID: 2428483
[TBL] [Abstract][Full Text] [Related]
25. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
Aoki N; Moroi M; Matsuda M; Tachiya K
J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activation at low temperatures in plasma samples containing therapeutic concentrations of tissue-type plasminogen activator or other thrombolytic agents.
Rijken DC; Seifried E; Barrett-Bergshoeff MM; Dooijewaard G
Thromb Haemost; 1990 Aug; 64(1):47-52. PubMed ID: 2125758
[TBL] [Abstract][Full Text] [Related]
27. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.
Harpel PC
J Clin Invest; 1981 Jul; 68(1):46-55. PubMed ID: 6166634
[TBL] [Abstract][Full Text] [Related]
28. Effects of native and denatured whey proteins on plasminogen activator activity.
Rippel KM; Nielsen SS; Hayes KD
J Dairy Sci; 2004 Aug; 87(8):2344-50. PubMed ID: 15328255
[TBL] [Abstract][Full Text] [Related]
29. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
Rouy D; Anglés-Cano E
Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
[TBL] [Abstract][Full Text] [Related]
30. Use of chromogenic substrate S-2251 for determination of plasminogen activator in rat ovaries.
Shimada H; Mori T; Takada A; Takada Y; Noda Y; Takai I; Kohda H; Nishimura T
Thromb Haemost; 1981 Aug; 46(2):507-10. PubMed ID: 7197812
[TBL] [Abstract][Full Text] [Related]
31. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma.
Verheijen JH; Mullaart E; Chang GT; Kluft C; Wijngaards G
Thromb Haemost; 1982 Dec; 48(3):266-9. PubMed ID: 6891841
[TBL] [Abstract][Full Text] [Related]
32. Homocysteine and its thiolactone impair plasmin activity induced by urokinase or streptokinase in vitro.
Kolodziejczyk-Czepas J; Talar B; Nowak P; Olas B; Wachowicz B
Int J Biol Macromol; 2012 Apr; 50(3):754-8. PubMed ID: 22197896
[TBL] [Abstract][Full Text] [Related]
33. In vitro simulation of thrombolysis inhibition.
Stief TW
Clin Appl Thromb Hemost; 2008 Apr; 14(2):234-7. PubMed ID: 18160584
[TBL] [Abstract][Full Text] [Related]
34. Ultrasensitive fluorogenic substrates for serine proteases.
Butenas S; DiLorenzo ME; Mann KG
Thromb Haemost; 1997 Oct; 78(4):1193-201. PubMed ID: 9364984
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous determination of free tissue-type and free urokinase-type plasminogen activators in biological fluids by a solid-phase immunoassay.
Kuo BS; Bjornsson TD
Anal Biochem; 1993 Feb; 209(1):70-8. PubMed ID: 8465964
[TBL] [Abstract][Full Text] [Related]
36. New fluorogenic peptide substrates for plasmin.
Kato H; Adachi N; Ohno Y; Iwanaga S; Takada K; Sakakibara S
J Biochem; 1980 Jul; 88(1):183-90. PubMed ID: 6447693
[TBL] [Abstract][Full Text] [Related]
37. Influence of coagulation on the activation of plasminogen by streptokinase and urokinase.
Takada A; Urano T; Takada Y
Thromb Haemost; 1979 Oct; 42(3):901-8. PubMed ID: 505405
[TBL] [Abstract][Full Text] [Related]
38. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities.
Husain SS
Biochemistry; 1991 Jun; 30(23):5797-805. PubMed ID: 1828371
[TBL] [Abstract][Full Text] [Related]
39. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
[TBL] [Abstract][Full Text] [Related]
40. Development of plasma kallikrein selective inhibitors.
Okada Y; Tsuda Y; Tada M; Wanaka K; Hijikata-Okunomiya A; Okamoto U; Okamoto S
Biopolymers; 1999; 51(1):41-50. PubMed ID: 10380351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
